Indian generic pharmaceutical firms are preparing for multiple US tariff outcomes. The focus is on how tariff changes can influence costs, demand, and margins under uncertainty.
Related current affairs
- Trump’s tariff threat on generics: Why it matters for Indian pharma firms
- Trump’s tariff threat on generics: What it could mean for Indian pharma firms
- Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
- Indian pharma sees little immediate threat from Trump’s 200% tariff plan
- India Must Build Resilient, Globally Integrated Healthcare Supply Chains: Commerce and Industry Minister at Bharat Health Global Expo 2026
- America’s tariff state is expanding. India must be patient